A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University
• Collaborator: Millennium Pharmaceuticals, Inc.
• Treatments: Bortezomib

Criteria

Inclusion Criteria:

• Histologically confirmed malignancy

• Requiring at least grade 2 weeks of radiation therapy

• Solid tumors of the central nervous system, head and neck area, and cervix

• World Health Organization (WHO) performance status equal to or less than 2

Exclusion Criteria:

• Equal to or greater than grade 2 peripheral neuropathy

• Myocardial infarction within 6 months

• Hypersensitivity to bortezomib, boron, or mannitol